Investigators Slow Growth by Starving Triple-Negative Breast Cancer Cells

Investigators from the Brazilian Biosciences National Laboratory have developed a strategy for slowing the growth of triple-negative breast cancer (TNBC) that involves cutting cancerous cells off from vital food sources.
The study, published in the Journal of Biological Chemistry, focused on TNBC tumors, which often lack estrogen progesterone receptors and human epidermal growth factor receptor 2 proteins. These are present in other breast cancers and permit certain targeted therapies. Since these types of tumors vary in genetic makeup, it has been a difficult task to find new markers to guide treatment.
Therefore, the investigators looked to glutamine and fatty acids, 2 well-known cancer food sources that tumors use to grow and survive. Glutamine, in particular, is incredibly important to tumor growth since it offers energy, carbon, nitrogen, and antioxidant properties.
Investigators found that by starving the cells by blocking glutamine and fatty acid metabolism, cancer cell growth and migration slowed.
They used the drug known as telaglenastat (CB-839), which prevents the processing of glutamine by deactivating the enzyme glutaminase and is currently in clinical trials to treat TNBC and other tumor types.
According to the press release, the molecular pathways that process lipids in the resistant cells were dramatically altered, said Sandra Martha Gomes Dias, a cancer researcher at the Brazilian Biosciences National Laboratory. In particular, levels of the enzymes CPT1 and CPT2, which are critical for fatty acid metabolism, were increased.
"CPT1 and 2 act as gateways for the entrance of fatty acids into mitochondria, where they will be used as fuel for energy production," Dias said in the press release. "Our hypothesis was that closing this gateway by inhibiting CPT1 in combination with glutaminase inhibition would decrease growth and migration of CB-839-resistant TNBC cells."
According to Dias, the double inhibition slowed proliferation and migration in resistant TNBC cells more than individual inhibition of either CPT1 or glutaminase. These results provide new genetic markers to guide drug choices in patients with TNBC, the study authors concluded.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.
Colon cancer may spread to other parts of the body before original tumors are clinically detectable.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.